SECURITIES PURCHASE AGREEMENT
EXHIBIT
99.2
This
Securities Purchase Agreement (this “Agreement”)
is dated as of March 20, 2007, between PreMD Inc., a Canadian corporation (the
“Company”),
and each purchaser identified on the signature pages hereto (each, including
its
successors and assigns, a “Purchaser”
and collectively the “Purchasers”).
WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant
to
Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”),
and Rule 506 promulgated thereunder, the Company desires to issue and sell
to
each Purchaser, and each Purchaser, severally and not jointly, desires to
purchase from the Company, securities of the Company as more fully described
in
this Agreement.
NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
and for other good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and each Purchaser agree as
follows:
ARTICLE
I.
DEFINITIONS
1.1 Definitions
Unless otherwise indicated, all references to dollars or currency in this
Agreement are to Canadian dollars. In addition to the terms defined elsewhere
in
this Agreement, for all purposes of this Agreement, the following terms have
the
meanings set forth in this Section 1.1:
“Action”
shall have the meaning ascribed to such term in Section 3.1(j).
“Affiliate”
means any Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common control with
a
Person as such terms are used in and construed under Rule 405 under the
Securities Act. With respect to a Purchaser, any investment fund or managed
account that is managed on a discretionary basis by the same investment manager
as such Purchaser will be deemed to be an Affiliate of such
Purchaser.
“Business
Day”
means any day except Saturday, Sunday, any day which is a federal legal holiday
in the United States or any day on which banking institutions in the State
of
New York are authorized or required by law or other governmental action to
close.
“Canadian
Securities Commissions”
means the securities commission or securities regulatory authority in each
of
the Provinces of Canada;
“Canadian
Securities Laws”
means all acts, rules, regulations and published policies promulgated or
otherwise adopted from time to time by any Canadian Securities Commission or
other authority having jurisdiction, and the rules and policies of the
TSX;
“Closing”
means the closing of the purchase and sale of the Securities pursuant to Section
2.1.
“Closing
Date”
means the Trading Day when all of the Transaction Documents have been executed
and delivered by the applicable parties thereto, and all conditions precedent
to
(i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the
Company’s obligations to deliver the Securities have been satisfied or
waived.
“Commission”
means the Securities and Exchange Commission.
“Common
Stock”
means the common stock of the Company, no par value per share, and any other
class of securities into which such securities may hereafter be reclassified
or
changed into.
“Common
Stock Equivalents”
means any securities of the Company or the Subsidiaries which would entitle
the
holder thereof to acquire at any time Common Stock, including, without
limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exercisable or exchangeable
for, or otherwise entitles the holder thereof to receive, Common
Stock.
“Company
Counsel”
means Xxxx & Berlis LLP.
“Continuous
Disclosure Reports”
shall have the meaning ascribed to such term in Section 3.1(h).
“Disclosure
Schedules”
means the Disclosure Schedules of the Company delivered concurrently herewith.
“Effective
Date”
means the date that the initial Registration Statement filed by the Company
pursuant to the Registration Rights Agreement is first declared effective by
the
Commission.
“Evaluation
Date”
shall have the meaning ascribed to such term in Section 3.1(r).
“Exchange
Act”
means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.
“Exempt
Issuance”
means the issuance of (a) shares of Common Stock or options to employees,
officers, consultants or directors of the Company pursuant to any stock or
option plan duly adopted for such purpose, by a majority of the non-employee
members of the Board of Directors of the Company or a majority of the members
of
a committee of non-employee directors established (provided, however, any such
issuance(s) to consultants shall not exceed 500,000 shares of Common Stock
and
Common Stock Equivalents (subject to reverse and forward stock splits and the
like), in the aggregate, in any 12 month period), (b) securities upon the
exercise or exchange of or conversion of any Securities issued hereunder and/or
other securities exercisable or exchangeable for or convertible into shares
of
Common Stock issued and outstanding on the date of this Agreement, provided
that
such securities have not been amended since the date of this Agreement to
increase the number of such securities or to decrease the exercise,
2
exchange
or conversion price of such securities, and (c) securities issued pursuant
to
acquisitions or strategic transactions approved by a majority of the
disinterested directors of the Company, provided that any such issuance shall
only be to a Person which is, itself or through its subsidiaries, an operating
company in a business synergistic with the business of the Company and in
which
the Company receives benefits in addition to the investment of funds, but
shall
not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business
is
investing in securities.
“FWS”
means Xxxxxxx Xxxxxxxxx & Xxxxx LLP with offices located at 000 Xxxxxxxxx
Xxxxxx, Xxxxx 0000, Xxx Xxxx, Xxx Xxxx 00000-0000.
“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).
“Indebtedness”
shall have the meaning ascribed to such term in Section 3.1(aa).
“Intellectual
Property Rights”
shall have the meaning ascribed to such term in Section 3.1(o).
“Legend
Removal Date”
shall have the meaning ascribed to such term in Section 4.1(c).
“Liens”
means a lien, charge, security interest, encumbrance, right of first refusal,
preemptive right or other restriction.
“Material
Adverse Effect”
shall have the meaning assigned to such term in Section 3.1(b).
“Material
Permits”
shall have the meaning ascribed to such term in Section 3.1(m).
“NI
45-106”
means National Instrument 45-106 - Prospectus and Registration Exemptions,
adopted by the Canadian Securities Commissions and effective September 14,
2005,
as such Instrument may be amended from time to time, or any similar instrument,
rule or regulation hereafter adopted by any Canadian Securities Commissions
having substantially the effect as such Instrument.
“Participation
Maximum”
shall have the meaning ascribed to such term in Section 4.12(a).
“Per
Share Purchase Price”
equals Cdn. $1.33, subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common
Stock that occur after the date of this Agreement.
“Person”
means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint
stock company, government (or an agency or subdivision thereof) or other entity
of any kind.
“Pre-Notice”
shall have the meaning ascribed to such term in Section 4.12(b).
3
“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without
limitation, an informal investigation or partial proceeding, such as a
deposition), whether commenced or threatened.
“Purchaser
Party”
shall have the meaning ascribed to such term in Section 4.8.
“Registration
Rights Agreement”
means the Registration Rights Agreement, dated the date hereof, among the
Company and the Purchasers, in the form of Exhibit
A
attached hereto.
“Registration
Statement”
means a registration statement meeting the requirements set forth in the
Registration Rights Agreement and covering the resale by the Purchasers of
the
Shares and the Warrant Shares.
“Required
Approvals”
shall have the meaning ascribed to such term in Section 3.1(e).
“Rule
144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act,
as
such Rule may be amended from time to time, or any similar rule or regulation
hereafter adopted by the Commission having substantially the same effect as
such
Rule.
“Securities”
means the Shares, the Warrants and the Warrant Shares.
“Securities
Act”
means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.
“SEDAR”
means the System for Electronic Document Analysis and Retrieval.
“Shares”
means the shares of Common Stock issued or issuable to each Purchaser pursuant
to this Agreement.
“Short
Sales”
means all “short sales” as defined in Rule 200 of Regulation SHO under the
Exchange Act (but
shall not be deemed to include the location and/or reservation of borrowable
shares of Common Stock).
“Subscription
Amount”
means, as to each Purchaser, the aggregate amount to be paid for Shares and
Warrants purchased hereunder as specified below such Purchaser’s name on the
signature page of this Agreement and next to the heading “Subscription Amount,”
in Canadian dollars and in immediately available funds.
“Subsequent
Financing”
shall have the meaning ascribed to such term in Section 4.12.
“Subsequent
Financing Notice”
shall have the meaning ascribed to such term in Section 4.12.
“Subsidiary”
means any subsidiary of the Company as set forth on Schedule
3.1(a),
and shall, where applicable, include any subsidiary of the Company formed or
acquired after the date hereof.
4
“Trading
Day”
means a day on which the New York Stock Exchange is open for
trading.
“Trading
Market”
means the following exchanges or markets on which the Common Stock is listed
or
quoted for trading on the date in question: the TSX, the American Stock Exchange
(the “AMEX”), the New York Stock Exchange, any facet of the NASDAQ Stock Market,
LLC (e.g. the Nasdaq Capital Market, the Nasdaq Global Market, or the Nasdaq
Global Select Market), or the OTC Bulletin Board.
“Transaction
Documents”
means this Agreement, the Warrants, the Registration Rights Agreement and any
other documents or agreements executed in connection with the transactions
contemplated hereunder.
“Transfer
Agent”
means Equity
Transfer & Trust Company f/k/a Equity Transfer Services, 000 Xxxxxxxxxx
Xxxxxx, Xxxxx 000, Xxxxxxx XX X0X 0X0, Xxxxxx, Toll Free: 0 (000) 000-0000,
Tel:
(000) 000-0000, Fax: (000) 000-0000, E-Mail: xxxx@xxxxxxxxxxxxxx.xxx,
and any successor transfer agent of the Company.
“TSX”
means the Toronto Stock Exchange.
“TSX
Legend Removal Date”
shall have the meaning ascribed to such term in Section 4.1(c).
“U.S.
Counsel”
means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., with offices located
at Xxx Xxxxxxxxx Xxxxxx, Xxxxxx, Xxxxxxxxxxxxx 00000.
“VWAP”
means, for any date, the price determined by the first of the following clauses
that applies: (a) if the Common Stock is then listed or quoted on a Trading
Market, the daily volume weighted average price of the Common Stock for such
date (or the nearest preceding date) on the Trading Market on which the Common
Stock is then listed or quoted for trading as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York
City
time); (b) if the Common Stock is not then quoted for trading on any
Trading Market and if prices for the Common Stock are then reported in the
“Pink
Sheets” published by Pink Sheets, LLC (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price
per
share of the Common Stock so reported; or (c) in all other cases, the fair
market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the Purchasers of a majority in interest
of
the Shares then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.
“Warrants”
means collectively the Common Stock purchase warrants delivered to the
Purchasers at the Closing in accordance with Section 2.2(a) hereof, which
Warrants shall be exercisable immediately and have a term of exercise equal
to 3
years from their date of issuance, in the form of Exhibit
C
attached hereto.
“Warrant
Shares”
means the shares of Common Stock issuable upon exercise of the
Warrants.
5
ARTICLE
II.
PURCHASE
AND SALE
2.1 Closing.
On the Closing Date, upon the terms and subject to the conditions set forth
herein, substantially concurrent with the execution and delivery of this
Agreement by the parties hereto, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase, in the aggregate, up to Cdn.$
3,889,878 of Shares and Warrants. Each Purchaser shall deliver to the Company,
via wire transfer (in accordance with the wire transfer instructions set out
in
Annex B attached hereto) or a certified check made payable to “Xxxx & Berlis
LLP in Trust”, in immediately available funds equal to its Subscription Amount
and the Company shall deliver to each Purchaser its respective Shares and a
Warrant as determined pursuant to Section 2.2(a), and the Company and each
Purchaser shall deliver the other items set forth in Section 2.2 deliverable
at
the Closing. Upon satisfaction of the covenants and conditions set forth in
Sections 2.2 and 2.3, the Closing shall occur at the offices of FWS, or such
other location as the parties shall mutually agree.
2.2 Deliveries
(a) On
or prior to the Closing Date, the Company shall deliver or cause to be delivered
to each Purchaser the following:
(i) this
Agreement duly executed by the Company;
(ii) a
legal opinion of U.S. Counsel, substantially in the form of Exhibit
B-1
attached hereto;
(iii) a
legal opinion of Company Counsel, substantially in the form of Exhibit
B-2
attached hereto;
(iv) a
certificate evidencing a number of Shares equal to such Purchaser’s Subscription
Amount divided by the Per Share Purchase Price, registered in the name
of such Purchaser;
(v) a
Warrant registered in the name of such Purchaser to purchase up to a number
of
shares of Common Stock equal to 50% of the Shares issuable to such Purchaser
hereunder, with an exercise price equal to Cdn. $1.66, subject to adjustment
therein; and
(vi) the
Registration Rights Agreement duly executed by the Company.
(b) On
or prior to the Closing Date, each Purchaser shall deliver or cause to be
delivered to the Company the following:
(i) this
Agreement duly executed by such Purchaser;
(ii) such
Purchaser’s Subscription Amount by wire transfer to the account designated in
writing by the Company;
(iii) the
Registration Rights Agreement duly executed by such Purchaser; and
6
(iv) if
the Purchaser is a resident of Canada, a completed and executed "Certificate
of
Accredited Investor" in the form attached hereto as
Annex C.
2.3 Closing
Conditions.
(a)
The
obligations of the Company hereunder in connection with the Closing are subject
to the following conditions being met:
(i) the
accuracy in all material respects on the Closing Date of the representations
and
warranties of the Purchasers contained herein;
(ii) all
obligations, covenants and agreements of each Purchaser required to be performed
at or prior to the Closing Date shall have been performed;
(iii) the
Company shall have obtained conditional TSX approval of the transactions
contemplated in this Agreement, and the Company shall have complied with all
of
the conditions set forth in the conditional acceptance letter of the TSX to
be
complied with prior to the Closing Date; and
(iv) the
AMEX shall have accepted the Company’s Listing of Additional Shares application
and approved the listing of the Shares and Warrant Shares; and
(v) the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this
Agreement.
(b) The
respective obligations of the Purchasers hereunder in connection with the
Closing are subject to the following conditions being met:
(i) the
accuracy in all material respects on the Closing Date of the representations
and
warranties of the Company contained herein;
(ii)
all
obligations, covenants and agreements of the Company required to be performed
at
or prior to the Closing Date shall have been performed;
(iii) the
Company shall have obtained conditional TSX approval of the transactions
contemplated in this Agreement, and the Company shall have complied with all
of
the conditions set forth in the conditional acceptance letter of the TSX to
be
complied with prior to the Closing Date;
(iv) the
AMEX shall have accepted the Company’s Listing of Additional Shares application
with respect to the Shares and Warrant Shares;
(v) the
delivery by the Company of the items set forth in Section 2.2(a) of this
Agreement;
(vi) there
shall have been no Material Adverse Effect with respect to the Company since
the
date hereof; and
7
(vii) from
the date hereof to the Closing Date, trading in the Common Stock shall not
have
been suspended by the Commission or the Company’s principal Trading Market
(except for any suspension of trading of limited duration agreed to by the
Company, which suspension shall be terminated prior to the Closing), and,
at any
time prior to the Closing Date, trading in securities generally as reported
by
Bloomberg L.P. shall not have been suspended or limited, or minimum prices
shall
not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been
declared either by the United States or New York State authorities nor shall
there have occurred any material outbreak or escalation of hostilities or
other
national or international calamity of such magnitude in its effect on, or
any
material adverse change in, any financial market which, in each case, in
the
reasonable judgment of each Purchaser, makes it impracticable or inadvisable
to
purchase the Securities at the Closing.
ARTICLE
III.
REPRESENTATIONS
AND WARRANTIES
3.1 Representations
and Warranties of the Company. Except
as set forth in the Disclosure Schedules which Disclosure Schedules shall be
deemed a part hereof and shall qualify any representation or otherwise made
herein to the extent of the disclosure contained in the corresponding section
of
the Disclosure Schedules, the Company hereby makes the following representations
and warranties to each Purchaser:
(a) Subsidiaries.
All of the direct and indirect subsidiaries of the Company are set forth on
Schedule
3.1(a).
Except as disclosed on Schedule 3.1(a), the Company owns, directly or
indirectly, all of the capital stock or other equity interests of each
Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully
paid, non-assessable and free of preemptive and similar rights to subscribe
for
or purchase securities. If the Company has no subsidiaries, then all other
references to the Subsidiaries or any of them in the Transaction Documents
shall
be disregarded.
(b) Organization
and Qualification.
The Company and each of the Subsidiaries is an entity duly incorporated or
otherwise organized, validly existing and in good standing under the laws of
the
jurisdiction of its incorporation or organization (as applicable), with the
requisite power and authority to own and use its properties and assets and
to
carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation or default of any of the provisions of its respective
certificate or articles of incorporation, bylaws or other organizational or
charter documents. Each of the Company and the Subsidiaries is duly qualified
to
conduct business and is in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except where the
failure to be so qualified or in good standing, as the case may be, could not
have or reasonably be expected to result in (i) a material adverse effect on
the
legality, validity or enforceability of any Transaction Document, (ii) a
material
8
adverse
effect on the results of operations, assets, business, prospects or condition
(financial or otherwise) of the Company and the Subsidiaries, taken as a
whole,
or (iii) a material adverse effect on the Company’s ability to perform in any
material respect on a timely basis its obligations under any Transaction
Document (any of (i), (ii) or (iii), a “Material
Adverse Effect”)
and no Proceeding has been instituted in any such jurisdiction revoking,
limiting or curtailing or seeking to revoke, limit or curtail such power
and
authority or qualification.
(c) Authorization;
Enforcement.
The Company has the requisite corporate power and authority to enter into and
to
consummate the transactions contemplated by each of the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of each of the Transaction Documents by the Company
have
been duly authorized by all necessary action on the part of the Company, and
the
consummation by the Company of the transactions contemplated hereby and thereby
have been, or will be prior to Closing, duly authorized by all necessary action
on the part of the Company and no further action is or will be required by
the
Company, its board of directors or its stockholders in connection therewith
other than in connection with the Required Approvals. Each Transaction Document
has been (or upon delivery will have been) duly executed by the Company and,
when delivered in accordance with the terms hereof and thereof, will constitute
the valid and binding obligation of the Company enforceable against the Company
in accordance with its terms except (i) as limited by general equitable
principles and applicable bankruptcy, insolvency, reorganization, moratorium
and
other laws of general application affecting enforcement of creditors’ rights
generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar
as
indemnification and contribution provisions may be limited by applicable
law.
(d) No
Conflicts.
The execution, delivery and performance of the Transaction Documents by the
Company, the issuance and sale of the Securities and the consummation by the
Company of the other transactions contemplated hereby and thereby do not and
will not (i) conflict with or violate any provision of the Company’s or any
Subsidiary’s certificate or articles of incorporation, bylaws or other
organizational or charter documents, or (ii) conflict with, or constitute a
default (or an event that with notice or lapse of time or both would become
a
default) under, result in the creation of any Lien upon any of the properties
or
assets of the Company or any Subsidiary, or give to others any rights of
termination, amendment, acceleration or cancellation (with or without notice,
lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or Subsidiary debt or otherwise) or other
understanding to which the Company or any Subsidiary is a party or by which
any
property or asset of the Company or any Subsidiary is bound or affected, or
(iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the Company or
a
Subsidiary is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company or a Subsidiary
is bound or affected; except in the case of each of clauses (ii) and (iii),
such
as could not have or reasonably be expected to result in a Material Adverse
Effect.
9
(e) Filings,
Consents and Approvals.
The Company is not required to obtain any consent, waiver, authorization or
order of, give any notice to, or make any filing or registration
with, any court or other federal, state, provincial, local or other governmental
authority or other Person in connection with the execution, delivery and
performance by the Company of the Transaction Documents, other than (i) filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the
Commission of the Registration Statement, (iii) application(s) to each
applicable Trading Market for the listing of the Securities for trading thereon
in the time and manner required thereby and (iv) the filing of Form D with
the
Commission and such filings as are required to be made under applicable state
securities laws (collectively, the “Required
Approvals”).
(f) Issuance
of the Securities.
The Securities are duly authorized and, when issued and paid for in accordance
with the applicable Transaction Documents, will be duly and validly issued,
fully paid and nonassessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer provided for in the Transaction Documents.
The Warrant Shares, when issued in accordance with the terms of the Transaction
Documents, will be validly issued, fully paid and nonassessable, free and clear
of all Liens imposed by the Company other than restrictions on transfer provided
for in the Transaction Documents. The Company has reserved from its duly
authorized capital stock the maximum number of shares of Common Stock issuable
pursuant to this Agreement and the Warrants.
(g) Capitalization.
The capitalization of the Company is as set forth on Schedule
3.1(g),
which Schedule
3.1(g)
shall also include the number of shares of Common Stock owned beneficially,
and
of record, by Affiliates of the Company as of the date hereof. The Company
has
not issued any capital stock since its most
recently filed financial statements filed on SEDAR, other
than the issuance of 145,762 shares of Common Stock in satisfaction of the
payment of interest under the Company’s convertible debentures issued on August
30, 2005 in the original aggregate principal amount of approximately Cdn.
$10,000,000, or pursuant to the exercise of employee stock options under the
Company’s stock option plans, the issuance of shares of Common Stock to
employees pursuant to the Company’s employee stock purchase plans and pursuant
to the conversion or exercise of Common Stock Equivalents outstanding as of
the
date of the most recently filed financial statements filed on SEDAR. No Person
has any right of first refusal, preemptive right, right of participation, or
any
similar right to participate in the transactions contemplated by the Transaction
Documents. Except as a result of the purchase and sale of the Securities or
as
otherwise disclosed on Schedule 3.1(g), there are no outstanding options,
warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into
or
exercisable or exchangeable for, or giving any Person any right to subscribe
for
or acquire, any shares of Common Stock, or contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or
may
become bound to issue additional shares of Common Stock or Common Stock
Equivalents. The issuance and sale of the Securities will not obligate the
Company to issue shares of Common Stock or other securities to any Person (other
than the Purchasers) and will not result in a right of any holder of Company
securities to adjust the exercise, conversion, exchange or reset price under
any
of such securities. All of the outstanding shares of capital stock of the
Company are validly issued, fully paid and nonassessable, have been issued
in
compliance with all federal and state securities laws and Canadian Securities
Laws, and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase securities.
No
further approval or authorization of any stockholder, the Board of Directors
of
the Company or others is required for the issuance and sale of the Securities.
There are no stockholders agreements, voting agreements or other similar
agreements with respect to the Company’s capital stock to which the Company is a
party or, to the knowledge of the Company, between or among any of the Company’s
stockholders.
10
(h) Continuous
Disclosure Reports; Financial Statements.
The Company has filed all reports, schedules, forms, statements and other
documents required to be filed by the Company under the Canadian Securities
Laws, the Securities Act and the Exchange Act, including pursuant to Section
13(a) or 15(d) thereof, for the two years preceding the date hereof (or such
shorter period as the Company was required by law or regulation to file such
material) (the foregoing materials, including the exhibits thereto and documents
incorporated by reference therein, being collectively referred to herein as
the
“Continuous
Disclosure Reports”)
on a timely basis or has received a valid extension of such time of filing
and
has filed any such Continuous Disclosure Reports prior to the expiration of
any
such extension. As of their respective dates, the Continuous Disclosure Reports
complied in all material respects with the requirements of the Canadian
Securities Laws, the Securities Act and the Exchange Act, as applicable, and
none of the Continuous Disclosure Reports, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to
be
stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. The
financial statements of the Company included in the Continuous Disclosure
Reports comply in all material respects with applicable accounting requirements
and the rules and regulations of the Canadian Securities Commissions and the
Commission with respect thereto as in effect at the time of filing. Such
financial statements have been prepared in accordance with Canadian generally
accepted accounting principles applied on a consistent basis during the periods
involved (“GAAP”),
reconciled to United States generally accepted accounting principles in the
notes to the financial statements, except as may be otherwise specified in
such
financial statements or the notes thereto and except that unaudited financial
statements may not contain all footnotes required by GAAP, and fairly present
in
all material respects the financial position of the Company and its consolidated
subsidiaries as of and for the dates thereof and the results of operations
and
cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit adjustments. The Company
is a
reporting issuer or the equivalent only in Ontario and Quebec and is not in
default of any requirement of the securities laws of any of such provinces.
The
Securities will not be subject to a restricted period or statutory hold period
under Canadian Securities Laws or to any resale restriction under the policies
of the TSX which extends beyond four months and one day after the Closing
Date;
(i) Material
Changes; Undisclosed Events, Liabilities or Developments.
Since the date of the latest audited financial statements included within the
Continuous Disclosure Reports, except as specifically disclosed in a subsequent
Continuous Disclosure Report filed prior to the date hereof, (i) there has
been
no event, occurrence or development that has had or that could reasonably be
expected to result in a Material Adverse Effect, (ii) the Company has not
incurred any liabilities (contingent or otherwise) other than (A) trade payables
and accrued expenses incurred in the ordinary course of business consistent
with
past practice and (B) liabilities not required to be reflected in the Company’s
financial statements pursuant to GAAP or disclosed in filings made pursuant
to
Canadian Securities Laws, (iii) the Company has not altered its method of
accounting, (iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased,
redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer,
director or Affiliate, except pursuant to existing Company stock option plans.
The Company does not have pending before the Commission or any Canadian
Securities Commissions any request for confidential treatment of information.
Except for the issuance of the Securities contemplated by this Agreement, no
event, liability or development has occurred or exists with respect to the
Company or its Subsidiaries or their respective business, properties, operations
or financial condition, that would be required to be disclosed by the Company
under applicable securities laws at the time this representation is made or
deemed made that has not been publicly disclosed at least 1 Trading Day prior
to
the date that this representation is made.
11
(j) Litigation.
There is no action, suit, inquiry, notice of violation, proceeding or
investigation pending or, to the knowledge of the Company, threatened against
or
affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or
regulatory authority (federal, state, county, local or foreign) (collectively,
an “Action”)
which (i) adversely affects or challenges the legality, validity or
enforceability of any of the Transaction Documents or the Securities or (ii)
could, if there were an unfavorable decision, have or reasonably be expected
to
result in a Material Adverse Effect. Neither the Company nor any Subsidiary,
nor, to the knowledge of the Company, any director or officer thereof, is or
has
been the subject of any Action involving a claim of violation of or liability
under federal or state securities laws or a claim of breach of fiduciary duty.
There has not been, and to the knowledge of the Company, there is not pending
or
contemplated, any investigation by the Commission involving the Company or
any
current or former director or officer of the Company. Neither the Commission
nor
any Canadian Securities Commissions have issued any stop order or other order
suspending the effectiveness of any document or registration statement filed
by
the Company or any Subsidiary under the Canadian Securities Laws, the Exchange
Act or the Securities Act.
(k) Labor
Relations.
No material labor dispute exists or, to the knowledge of the Company, is
imminent with respect to any of the employees of the Company which could
reasonably be expected to result in a Material Adverse Effect. None of the
Company’s or its Subsidiaries’ employees is a member of a union that relates to
such employee’s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining
agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. No executive officer, to the knowledge of the
Company, is, or is now expected to be, in violation of any material term of
any
employment contract, confidentiality, disclosure or proprietary information
agreement or non-competition agreement, or any other contract or agreement
or
any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any
of
its Subsidiaries to any liability with respect to any of the foregoing matters.
The Company and its Subsidiaries are in compliance with all Canadian provincial
laws and regulations, and any other applicable U.S. federal or state or foreign
laws and regulations, relating to employment and employment practices, terms
and
conditions of employment and wages and hours, except where the failure to be
in
compliance could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.
12
(l) Compliance.
Neither the Company nor any Subsidiary (i) is in default under or in violation
of (and no event has occurred that has not been waived that, with notice or
lapse of time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received notice of
a
claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is
a
party or by which it or any of its properties is bound (whether or not such
default or violation has been waived), (ii) is in violation of any order of
any
court, arbitrator or governmental body, or (iii) is or has been in violation
of
any statute, rule or regulation of any governmental authority, including without
limitation all foreign, federal, state and local laws applicable to its business
and all such laws that affect the environment, except in each case as could
not
have or reasonably be expected to result in a Material Adverse
Effect.
(m) Regulatory
Permits.
The Company and the Subsidiaries possess all certificates, authorizations and
permits issued by the appropriate federal, state, local or foreign regulatory
authorities necessary to conduct their respective businesses as described in
the
Continuous Disclosure Reports, except where the failure to possess such permits
could not reasonably be expected to result in a Material Adverse Effect
(“Material
Permits”),
and neither the Company nor any Subsidiary has received any notice of
proceedings relating to the revocation or modification of any Material
Permit.
(n) Title
to Assets.
The Company and the Subsidiaries have good and marketable title in fee simple
to
all real property owned by them and good and marketable title in all personal
property owned by them that is material to the business of the Company and
the
Subsidiaries, in each case free and clear of all Liens, except for Liens as
do
not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company and
the Subsidiaries and Liens for the payment of federal, state or other taxes,
the
payment of which is neither delinquent nor subject to penalties. Any real
property and facilities held under lease by the Company and the Subsidiaries
are
held by them under valid, subsisting and enforceable leases with which the
Company and the Subsidiaries are in compliance.
(o) Patents
and Trademarks.
The Company and the Subsidiaries have, or have rights to use, all patents,
patent applications, trademarks, trademark applications, service marks, trade
names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or material for use in connection
with their respective businesses as described in the Continuous Disclosure
Reports and which the failure to so have could have a Material Adverse Effect
(collectively, the “Intellectual
Property Rights”).
Neither the Company nor any Subsidiary has received a notice (written or
otherwise) that any of the Intellectual Property Rights used by the Company
or
any Subsidiary violates or infringes upon the rights of any Person. To the
knowledge of the Company, all such Intellectual Property Rights are enforceable
and there is no existing infringement by another Person of any of the
Intellectual Property Rights. The Company and its Subsidiaries have taken
reasonable security measures to protect the secrecy, confidentiality and value
of all of their intellectual properties, except where failure to do so could
not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.
13
(p) Insurance.
The Company and the Subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as are prudent
and customary in the businesses in which the Company and the Subsidiaries are
engaged, including, but not limited to, directors and officers insurance
coverage at least equal to the aggregate Subscription Amount. Neither the
Company nor any Subsidiary has any reason to believe that it will not be able
to
renew its existing insurance coverage as and when such coverage expires or
to
obtain similar coverage from similar insurers as may be necessary to continue
its business without a significant increase in cost.
(q) Transactions
With Affiliates and Employees.
Except as set forth in the Continuous Disclosure Reports, none of the officers
or directors of the Company and, to the knowledge of the Company, none of the
employees of the Company is presently a party to any transaction with the
Company or any Subsidiary (other than for services as employees, officers and
directors), including any contract, agreement or other arrangement providing
for
the furnishing of services to or by, providing for rental of real or personal
property to or from, or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in
which any officer, director, or any such employee has a substantial interest
or
is an officer, director, trustee or partner, in each case in excess of $60,000
other than for (i) payment of salary or consulting fees for services rendered,
(ii) reimbursement for expenses incurred on behalf of the Company and (iii)
other employee benefits, including stock option agreements under any stock
option plan of the Company.
(r) Xxxxxxxx-Xxxxx;
Internal Accounting Controls.
The Company is in material compliance with all provisions of the Xxxxxxxx-Xxxxx
Act of 2002 which are applicable to it as of the Closing Date. The
Company and the Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed
in
accordance with management’s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii)
access to assets is permitted only in accordance with management’s general or
specific authorization, and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences. The Company has established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the Company and designed such disclosure controls and procedures
to ensure that information required to be disclosed by the Company in the
reports it files or submits under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the Commission’s
rules and forms. The Company’s certifying officers have evaluated the
effectiveness of the Company’s disclosure controls and procedures as of the end
of the period covered by the Company’s most recently filed periodic report under
the Exchange Act (such date, the “Evaluation
Date”).
The Company presented in its most recently filed periodic report under the
Exchange Act the conclusions of the certifying officers about the effectiveness
of the disclosure controls and procedures based on their evaluations as of
the
Evaluation Date. Since the Evaluation Date, there have been no changes in the
Company’s internal control over financial reporting (as such term is defined in
the Exchange Act) that has materially affected, or is reasonably likely to
materially affect, the Company’s internal control over financial
reporting.
14
(s) Certain
Fees.
No brokerage or finder’s fees or commissions are or will be payable by the
Company to any broker, financial advisor or consultant, finder, placement agent,
investment banker, bank or other Person with respect to the transactions
contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or
on
behalf of other Persons for fees of a type contemplated in this Section that
may
be due in connection with the transactions contemplated by the Transaction
Documents.
(t) Private
Placement.
Assuming the accuracy of the Purchasers representations and warranties set
forth
in Section 3.2, no registration under the Securities Act and no prospectus
under
Canadian Securities Laws are required for the offer and sale of the Securities
by the Company to the Purchasers as contemplated hereby. The issuance and sale
of the Securities hereunder does not contravene the rules and regulations of
the
Trading Market.
(u) Investment
Company.
The Company is not, and is not an Affiliate of, and immediately after receipt
of
payment for the Securities, will not be or be an Affiliate of, an “investment
company” within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become
subject to the Investment Company Act of 1940, as amended.
(v) Registration
Rights.
Other than each of the Purchasers, no Person has any right to cause the Company
to effect the registration under the Securities Act of any securities of the
Company.
(w) Listing
and Maintenance Requirements.
The Company’s Common Stock is listed on the TSX and is registered pursuant to
Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action
designed to, or which to its knowledge is likely to have the effect of,
terminating the registration of the Common Stock under the Exchange Act or
the
listing of the Common Stock on the TSX nor has the Company received any
notification that the Commission or the TSX, respectively, are contemplating
terminating such registration. The Company has not, in the 12 months preceding
the date hereof, received notice from any Trading Market on which the Common
Stock is or has been listed or quoted to the effect that the Company is not
in
compliance with the listing or maintenance requirements of such Trading Market.
The Company is, and has no reason to believe that it will not in the foreseeable
future continue to be, in compliance with all such listing and maintenance
requirements.
(x) Application
of Takeover Protections.
The Company and its board of directors have taken all necessary action, if
any,
in order to render inapplicable any control share acquisition, business
combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company’s certificate of
incorporation (or similar charter documents) or the laws of its country of
incorporation that is or could become applicable to the Purchasers as a result
of the Purchasers and the Company fulfilling their obligations or exercising
their rights under the Transaction Documents, including without limitation
as a
result of the Company’s issuance of the Securities and the Purchasers’ ownership
of the Securities.
15
(y) Disclosure.
Except with respect to the material terms and conditions of the transactions
contemplated by the Transaction Documents, the Company confirms that neither
it
nor any other Person acting on its behalf has provided any of the Purchasers
or
their agents or counsel with any information that it believes constitutes or
might constitute material, non-public information. The Company understands
and
confirms that the Purchasers will rely on the foregoing representation in
effecting transactions in securities of the Company. All disclosure furnished
by
or on behalf of the Company to the Purchasers regarding the Company, its
business and the transactions contemplated hereby, including the Disclosure
Schedules, is true and correct in all material respects and does not contain
any
untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in light of the circumstances
under which they were made, not misleading. The press releases disseminated
by
the Company during the twelve months preceding the date of this Agreement taken
as a whole do not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they
were
made and when made, not misleading. The Company acknowledges and agrees that
no
Purchaser makes or has made any representations or warranties with respect
to
the transactions contemplated hereby other than those specifically set forth
in
Section 3.2 hereof.
(z) No
Integrated Offering.
Assuming the accuracy of the Purchasers’ representations and warranties set
forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any
Person acting on its or their behalf has, directly or indirectly, made any
offers or sales of any security or solicited any offers to buy any security,
under circumstances that would cause this offering of the Securities to be
integrated with prior offerings by the Company for purposes of (i) the
Securities Act which would require the registration of any such securities
under
the Securities Act, or (ii) any applicable shareholder approval provisions
of
any Trading Market on which any of the securities of the Company are listed
or
designated.
(aa) Solvency.
Based on the consolidated financial condition of the Company as of the Closing
Date, after giving effect to the receipt by the Company of the proceeds from
the
sale of the Securities hereunder, (i) the fair saleable value of the Company’s
assets exceeds the amount that will be required to be paid on or in respect
of
the Company’s existing debts and other liabilities (including known contingent
liabilities) as they mature; (ii) the Company’s assets do not constitute
unreasonably small capital to carry on its business as now conducted and as
proposed to be conducted including its capital needs taking into account the
particular capital requirements of the business conducted by the Company, and
projected capital requirements and capital availability thereof; and (iii)
to
the knowledge of the Company, the current cash flow of the Company, together
with the proceeds the Company would receive, were it to liquidate all of its
assets, after taking into account all anticipated uses of the cash, would be
sufficient to pay all amounts on or in respect of its liabilities when such
amounts are required to be paid. The Company does not intend to incur debts
beyond its ability to pay such debts as they mature (taking into account the
timing and amounts of cash to be payable on or in respect of its debt). The
Company has no knowledge of any facts or circumstances which lead it to believe
that it will file for reorganization or liquidation under the bankruptcy or
reorganization laws of any jurisdiction within one year from the Closing Date.
Schedule 3.1(aa) sets forth as of the date thereof all outstanding secured
and
unsecured Indebtedness of the Company or any Subsidiary, or for which the
Company or any Subsidiary has commitments. For the purposes of this Agreement,
“Indebtedness”
means (a) any liabilities for borrowed money or amounts owed in excess of
$50,000 (other than trade accounts payable incurred in the ordinary course
of
business), (b) all guarantees, endorsements and other contingent obligations
in
respect of Indebtedness of others, whether or not the same are or should be
reflected in the Company’s balance sheet (or the notes thereto), except
guarantees by endorsement of negotiable instruments for deposit or collection
or
similar transactions in the ordinary course of business; and (c) the present
value of any lease payments
in excess of $50,000 due under leases required to be capitalized in accordance
with GAAP. Neither
the Company nor any Subsidiary is in default with respect to any
Indebtedness.
16
(bb) Tax
Status.
Except for matters that would not, individually or in the aggregate, have or
reasonably be expected to result in a Material Adverse Effect, the Company
and
each Subsidiary has filed all necessary federal, provincial, state and foreign
income and franchise tax returns and has paid or accrued all taxes shown as
due
thereon, and the Company has no knowledge of a tax deficiency which has been
asserted or threatened against the Company or any Subsidiary.
(cc)
No
General Solicitation.
Neither the Company nor any Person acting on behalf of the Company has offered
or sold any of the Securities by any form of general solicitation or general
advertising. The Company has offered the Securities for sale only to the
Purchasers and certain other “accredited investors” within the meaning of Rule
501 under the Securities Act and NI 45-106.
(dd) Foreign
Corrupt Practices.
Neither the Company, nor to the knowledge of the Company, any agent or other
Person acting on behalf of the Company, has (i) directly or indirectly, used
any
funds for unlawful contributions, gifts, entertainment or other unlawful
expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or
to
any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company (or made
by
any Person acting on its behalf of which the Company is aware) which is in
violation of law, or (iv) violated in any material respect any provision of
the
Foreign Corrupt Practices Act of 1977, as amended.
(ee) Accountants.
The Company’s accounting firm is set forth on Schedule
3.1(ee)
of the Disclosure Schedule. To the knowledge and belief of the Company, such
accounting firm (i) is a registered public accounting firm as required by the
Exchange Act and (ii) shall express its opinion with respect to the financial
statements to be included in the Company’s Annual Report on Form 20-F for the
year ended December 31, 2006.
17
(ee) No
Disagreements with Accountants and Lawyers. There
are no disagreements of any kind presently existing, or reasonably anticipated
by the Company to arise, between the Company and the accountants and lawyers
formerly or presently employed by the Company which could affect the Company’s
ability to perform any of its obligations under any of the Transaction
Documents, and the Company is current with respect to any fees owed to its
accountants and lawyers.
(ff) Acknowledgment
Regarding Purchasers’ Purchase of Securities.
The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm’s length purchaser with respect to the Transaction
Documents and the transactions contemplated thereby. The Company further
acknowledges that no Purchaser is acting as a financial advisor or fiduciary
of
the Company (or in any similar capacity) with respect to the Transaction
Documents and the transactions contemplated thereby and any advice given by
any
Purchaser or any of their respective representatives or agents in connection
with the Transaction Documents and the transactions contemplated thereby is
merely incidental to the Purchasers’ purchase of the Securities. The Company
further represents to each Purchaser that the Company’s decision to enter into
this Agreement and the other Transaction Documents has been based solely on
the
independent evaluation of the transactions contemplated hereby by the Company
and its representatives.
(gg) Acknowledgement
Regarding Purchaser’s Trading Activity.
Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged
by the Company (i) that none of the Purchasers have been asked by the Company
to
agree, nor has any Purchaser agreed, to desist from purchasing or selling,
long
and/or short, securities of the Company, or “derivative” securities based on
securities issued by the Company or to hold the Securities for any specified
term; (ii) that past or future open market or other transactions by any
Purchaser, including Short Sales, and specifically including, without
limitation, Short Sales or “derivative” transactions, before or after the
closing of this or future private placement transactions, may negatively impact
the market price of the Company’s publicly-traded securities; (iii) that any
Purchaser, and counter-parties in “derivative” transactions to which any such
Purchaser is a party, directly or indirectly, presently may have a “short”
position in the Common Stock, and (iv) that each Purchaser shall not be deemed
to have any affiliation with or control over any arm’s length counter-party in
any “derivative” transaction. The
Company further understands and acknowledges that (a) one or more Purchasers
may
engage in hedging activities at various times during the period that the
Securities are outstanding, including, without limitation, during the periods
that the value of the Warrant Shares deliverable with respect to Securities
are
being determined and (b) such hedging activities (if any) could reduce the
value
of the existing stockholders' equity interests in the Company at and after
the
time that the hedging activities are being conducted. The Company
acknowledges that such aforementioned hedging activities do not constitute
a
breach of any of the Transaction Documents.
(hh) Regulation
M Compliance.
The Company has not, and to its knowledge no one acting on its behalf has,
(i)
taken, directly or indirectly, any action designed to cause or to result in
the
stabilization or manipulation of the price of any security of the
18
Company
to facilitate the sale or resale of any of the Securities, (ii) sold, bid
for,
purchased, or, paid any compensation for soliciting purchases of, any of
the
Securities, or (iii) paid or agreed to pay to any Person any compensation
for
soliciting another to purchase any other securities of the Company, other
than,
in the case of clauses (ii) and (iii), compensation paid to the Company’s
placement agent in connection with the placement of the
Securities.
(ii) FDA.
Except as disclosed on Schedule
3.1(ii),
as to each product subject to the jurisdiction of the U.S. Food and Drug
Administration (“FDA”)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations
thereunder (“FDCA”)
that is currently being manufactured, packaged, labeled, tested, distributed,
sold, and/or marketed by the Company or any of its Subsidiaries (each such
product, a “Pharmaceutical Product”), such Pharmaceutical Product is being
manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by
the Company in compliance with all applicable requirements under FDCA and
similar laws, rules and regulations relating to registration, investigational
use, premarket clearance, licensure, or application approval, good manufacturing
practices, good laboratory practices, good clinical practices, product listing,
quotas, labeling, advertising, record keeping and filing of reports, except
where the failure to be in compliance would not have a Material Adverse Effect.
There is no pending, completed or, to the Company's knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or
regulatory proceeding, charge, complaint, or investigation) against the Company
or any of its Subsidiaries, and none of the Company or any of its Subsidiaries
has received any notice, warning letter or other communication from the FDA
or
any other governmental entity, which (i) contests the premarket clearance,
licensure, registration, or approval of, the uses of, the distribution of,
the
manufacturing or packaging of, the testing of, the sale of, or the labeling
and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of,
requests the recall, suspension, or seizure of, or withdraws or orders the
withdrawal of advertising or sales promotional materials relating to, any
Pharmaceutical Product, (iii) imposes a clinical hold on any clinical
investigation by the Company or any of its Subsidiaries, (iv) enjoins production
at any facility of the Company or any of its Subsidiaries, (v) enters or
proposes to enter into a consent decree of permanent injunction with the Company
or any of its Subsidiaries, or (vi) otherwise alleges any violation of any
laws,
rules or regulations by the Company or any of its Subsidiaries, and which,
either individually or in the aggregate, would have a Material Adverse Effect.
The
properties, business and operations of the Company have been and are being
conducted in all material respects in accordance with all applicable laws,
rules
and regulations of the FDA. Except as disclosed on Schedule
3.1(ii),
the Company has not been informed by the FDA that the FDA will prohibit the
marketing, sale, license or use in the United States of any product proposed
to
be developed, produced or marketed by the Company or any of its Subsidiaries
nor
has the FDA expressed any concern as to approving or clearing for marketing
any
product being developed or proposed to be developed by the Company or any of
its
Subsidiaries.
(jj) Form
F-3 Eligibility.
The Company is eligible to register the resale of the Securities for resale
by
the Purchaser on Form F-3 promulgated under the Securities Act.
19
3.2 Representations
and Warranties of the Purchasers.
Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as
follows:
(a) Organization;
Authority.
Such Purchaser is an entity duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization with full right,
corporate or partnership power and authority to enter into and to consummate
the
transactions contemplated by the Transaction Documents and otherwise to carry
out its obligations hereunder and thereunder. The execution and delivery of
the
Transaction Documents and performance by such Purchaser of the transactions
contemplated by the Transaction Documents have been duly authorized by all
necessary corporate or similar action on the part of such Purchaser. Each
Transaction Document to which it is a party has been duly executed by such
Purchaser, and when delivered by such Purchaser in accordance with the terms
hereof, will constitute the valid and legally binding obligation of such
Purchaser, enforceable against it in accordance with its terms, except (i)
as
limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may
be
limited by applicable law.
(b) Own
Account.
Such Purchaser understands that the Securities are “restricted securities” in
the United States and have not been registered under the Securities Act or
any
applicable state securities law and is acquiring the Securities as principal
for
its own account and not with a view to or for distributing or reselling such
Securities or any part thereof in violation of the applicable Canadian
Securities Laws, the Securities Act or any applicable state securities law,
has
no present intention of distributing any of such Securities in violation of
applicable Canadian Securities Laws, the Securities Act or any applicable state
securities law and has no direct or indirect arrangement or understandings
with
any other persons to distribute or regarding the distribution of such Securities
(this representation and warranty not limiting such Purchaser’s right to sell
the Securities pursuant to the Registration Statement or otherwise in compliance
with applicable Canadian Securities Laws and federal and state securities laws)
in violation of the Canadian Securities Laws, the Securities Act or any
applicable state securities law. Such Purchaser is acquiring the Securities
hereunder in the ordinary course of its business.
(c) Purchaser
Status.
At the time such Purchaser was offered the Securities, it was, and at the date
hereof it is, and on each date on which it exercises any Warrants, it will
be an
“accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or
(a)(8) under the Securities Act and Section 1.1 of NI 45-106. Such Purchaser
is
not required to be registered as a broker-dealer under Section 15 of the
Exchange Act.
(d) Experience
of Such Purchaser.
Such Purchaser, either alone or together with its representatives, has such
knowledge, sophistication and experience in business and financial matters
so as
to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment.
Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such
investment.
20
(e) General
Solicitation.
Such Purchaser is not purchasing the Securities as a result of any
advertisement, article, notice or other communication regarding the Securities
published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or any other general
solicitation or general advertisement.
(f) Short
Sales and Confidentiality Prior To The Date Hereof.
Other than consummating the transactions contemplated hereunder, such Purchaser
has not, nor has any Person acting on behalf of or pursuant to any understanding
with such Purchaser, directly or indirectly executed any purchases or sales,
including Short Sales, of the securities of the Company during the period
commencing from
the time that such Purchaser first received a term sheet (written or oral)
from
the Company or any other Person representing the Company setting forth the
material terms of the transactions contemplated hereunder until the date hereof
(“Discussion
Time”).
Notwithstanding the foregoing, in the case of a Purchaser that is a
multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser's assets and the portfolio managers have
no
direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser's assets, the representation set
forth
above shall only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the Securities
covered by this Agreement. Other than to other Persons party to this Agreement,
such Purchaser has maintained the confidentiality of all disclosures made to
it
in connection with this transaction (including the existence and terms of this
transaction).
(g) No
Prospectus.
Such Purchaser acknowledges and agrees that no prospectus has been filed with
any Canadian Securities Commission or other regulatory body in connection with
the issuance of the Securities, such issuance is exempted from the prospectus
requirements of applicable securities legislation, and
(i)
|
the
Purchaser is restricted from using certain civil
remedies;
|
(ii)
|
the
Purchaser may not receive information that would otherwise be required
to
be provided; and
|
(iii)
|
the
Company is relieved from certain obligations that would otherwise
apply,
|
under
Canadian Securities Laws which would otherwise be available if the Securities
were sold pursuant to a prospectus.
ARTICLE
IV.
OTHER
AGREEMENTS OF THE PARTIES
4.1 Transfer
Restrictions.
(a) The
Securities may only be disposed of in compliance with Canadian Securities Laws
and the U.S. state and federal securities laws. In connection with any transfer
of Securities other than pursuant to Canadian Securities Laws, an effective
registration statement or Rule 144 in the U.S., to the Company, to an Affiliate
of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b),
the Company shall require the transferor thereof to provide to the Company
an
opinion of counsel selected by the transferor and reasonably acceptable to
the
Company, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that such transfer does not require
registration of such transferred Securities under the Securities Act. As a
condition of transfer, any such transferee shall agree in writing to be bound
by
the terms of this Agreement and shall have the rights of a Purchaser under
this
Agreement and the Registration Rights Agreement.
21
(b) The
Purchasers agree to the imprinting, so long as is required by this Section
4.1(b), of a legend on any of the Securities in the following form:
(i) UNLESS
PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT
TRADE THE SECURITY BEFORE [(insert
the date that is four months and a day after the Closing
Date)].
(ii) THE
SECURITIES [ISSUABLE UPON EXERCISE OF THE SECURITY] REPRESENTED BY THIS
CERTIFICATE ARE LISTED ON THE TORONTO STOCK EXCHANGE (“TSX”); HOWEVER, THE
SAID SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES
OF TSX SINCE THEY ARE NOT FREELY TRANSFERABLE, AND CONSEQUENTLY ANY
CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT “GOOD DELIVERY” IN SETTLEMENT OF
TRANSACTIONS ON TSX.
(iii) THESE
SECURITIES [AND THE SECURITIES INTO WHICH THESE SECURITIES ARE [EXERCISABLE]
HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN
EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL
TO
THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON
[EXERCISE] OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE
MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES, PROVIDED, HOWEVER,
ANY
TRANSFER OF THE SECURITIES RESULTING FROM SUCH PLEDGE MUST COMPLY WITH THE
FOREGOING.
22
The
Company acknowledges and agrees that a Purchaser may from time to time pledge
pursuant to a bona fide margin agreement with a registered broker-dealer
or
grant a security interest in some or all of the Securities to a financial
institution that is an “accredited investor” as defined in Rule 501(a) under the
Securities Act and who agrees to be bound by the provisions of this Agreement
and the Registration Rights Agreement and, if required under the terms of
such
arrangement, such Purchaser may transfer pledged or secured Securities to
the
pledgees or secured parties. Such a pledge or transfer would not be subject
to
approval of the Company and no legal opinion of legal counsel of the pledgee,
secured party or pledgor shall be required in connection therewith. Further,
no
notice shall be required of such pledge. At the appropriate Purchaser’s expense,
the Company will execute and deliver such reasonable documentation as a pledgee
or secured party of Securities may reasonably request in connection with
a
pledge or transfer of the Securities, including, if the Securities are subject
to registration pursuant to the Registration Rights Agreement, the preparation
and filing of any required prospectus supplement under Rule 424(b)(3) under
the
Securities Act or other applicable provision of the Securities Act to
appropriately amend the list of Selling Stockholders
thereunder.
(c) The
certificates evidencing the Shares and the Warrant Shares shall not require
the
legends set forth in Sections 4.1(b)(i) and 4.1(b)(ii) hereof if shares of
Common Stock are listed or quoted on the TSX or other Canadian securities
exchange, after four months and one day following the Closing Date (the
“TSX
Legend Removal Date”),
and shall not require any legend after such TSX Legend Removal Date, (including
any legend set forth in Sections 4.1(b)(i), 4.1(b)(ii) or 4.1(b)(iii) hereof):
(i) while a registration statement (including the Registration Statement)
covering the resale of such security is effective under the Securities Act,
or
(ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144,
or (iii) if such Shares or Warrant Shares are eligible for sale under Rule
144(k), or (iv) if such legend is not required under applicable requirements
of
the Securities Act (including judicial interpretations and pronouncements issued
by the staff of the Commission). The Company shall cause its counsel to issue
a
legal opinion to the Company’s transfer agent if required by the Company’s
transfer agent to effect the removal of legends hereunder. If all or any portion
of a Warrant is exercised at a time when no legend is required hereunder, then
such Warrant Shares shall be issued free of any legend. The Company agrees
at
such time as the legends are no longer required under this Section 4.1(c),
it
will, no later than three Trading Days following the delivery by a Purchaser
to
the Company or the Company’s transfer agent of a request to remove the
applicable restrictive legends together with the certificates representing
Shares or Warrant Shares issued with a restrictive legend (such third Trading
Day, the “Legend
Removal Date”),
deliver or cause to be delivered to such Purchaser a certificate representing
such shares that is free from all restrictive and other legends. The Company
may
not make any notation on its records or give instructions to any transfer agent
of the Company that enlarge the restrictions on transfer set forth in this
Section. Certificates for Securities subject to legend removal hereunder shall
be transmitted by the transfer agent of the Company to a Purchaser by crediting
the account of such Purchaser’s prime broker with the Depository Trust Company
through its Deposit Withdrawal Agent Commission system or another established
clearing corporation performing similar functions as directed by such Purchaser
if the Company is a participant in such system(s), and otherwise by physical
delivery to the address specified by such Purchaser.
(d) In
addition to such Purchaser’s other available remedies, the Company shall pay to
a Purchaser, in cash, as partial liquidated damages and not as a penalty, for
each $1,000 of Shares or Warrant Shares (based on the VWAP of the Common Stock
on the date such Securities are submitted to the Transfer Agent) delivered
for
removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading
Day (increasing to $20 per Trading Day five (5) Trading Days after such damages
have begun to accrue) for each Trading Day after the Legend Removal Date until
such certificate is delivered without a legend. Nothing herein shall limit
such
Purchaser’s right to pursue actual damages for the Company’s failure to deliver
certificates representing any Securities as required by the Transaction
Documents, and such Purchaser shall have the right to pursue all remedies
available to it at law or in equity including, without limitation, a decree
of
specific performance and/or injunctive relief.
23
(e) Each
Purchaser, severally and not jointly with the other Purchasers, agrees that
such
Purchaser will sell any Securities pursuant to either the registration
requirements of the Securities Act, including any applicable prospectus delivery
requirements, or an exemption therefrom, or pursuant to an exemption from the
prospectus and registration requirements pursuant to Canadian Securities Laws,
if applicable, and that if Securities are sold pursuant to a Registration
Statement, they will be sold in compliance with the plan of distribution set
forth therein, and acknowledges that the removal of the restrictive legend
from
certificates representing Securities as set forth in this Section 4.1 is
predicated upon the Company’s reliance upon this understanding.
4.2 Furnishing
of Information. Until the earliest of the time that (i) no Purchaser owns
Securities or (ii) the Warrants have expired, the Company covenants to timely
file (or obtain extensions in respect thereof and file within the applicable
grace period) all reports required to be filed by the Company after the date
hereof pursuant to the Exchange Act and Canadian Securities Laws even if the
Company is not then subject to the reporting requirements of the Exchange Act
or
any Canadian Securities Laws. As long as any Purchaser owns Securities, if
the
Company is not required to file reports pursuant to the Exchange Act or pursuant
to Canadian Securities Laws, it will prepare and furnish to the Purchasers
and
make publicly available in accordance with Rule 144(c) such information as
is
required for the Purchasers to sell the Securities under Rule 144. The Company
further covenants that it will take such further action as any holder of
Securities may reasonably request, to the extent required from time to time
to
enable such Person to sell such Securities without registration under the
Securities Act within the requirements of the exemption provided by Rule
144.
4.3 Integration.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise
negotiate in respect of any security (as defined in Section 2 of the Securities
Act) that would be integrated with the offer or sale of the Securities in a
manner that would require the registration under the Securities Act of the
sale
of the Securities to the Purchasers or that would be integrated with the offer
or sale of the Securities to the Purchasers for purposes of the rules and
regulations of any Trading Market such that it would require shareholder
approval prior to the closing of such other transaction unless shareholder
approval is obtained before the closing of such subsequent
transaction.
24
4.4 Securities
Laws Disclosure; Publicity. The Company shall, by 8:30 a.m. (New York City
time) on the Trading Day immediately following the date hereof, issue a press
release disclosing the material terms of the transactions contemplated hereby,
and, by 8:30 a.m. (New York City time) on the second Trading Day immediately
following the date hereof, issue (i) a Current Report on Form 6-K and
(ii) file a material change report with SEDAR, in each case disclosing the
material terms of the transactions contemplated hereby, and filing the
Transaction Documents as exhibits thereto. Neither the Company nor any Purchaser
shall issue any press release with respect to the transactions contemplated
hereby or otherwise make any such public statement without the prior consent
of
the Company, with respect to any press release of any Purchaser, or without
the
prior consent of the Purchasers of 66% or more of the Shares then outstanding
(or issuable hereunder, with respect to any press release prior to Closing),
with respect to any press release of the Company, which consent shall not
unreasonably be withheld or delayed, except if such disclosure is required
by
law, in which case the disclosing party shall promptly provide the other
party
with prior notice of such public statement or communication. Notwithstanding
the
foregoing, the Company shall not publicly disclose the name of any Purchaser,
or
include the name of any Purchaser in any filing with the Commission or any
regulatory agency or Trading Market, without the prior written consent of
such
Purchaser, except (i) as required by Canadian Securities Laws or U.S. federal
securities law in connection with (A) any registration statement contemplated
by
the Registration Rights Agreement; (B) the filing of a Form 45-106F1 with
the
applicable Canadian Securities Commissions pursuant to NI 45-106; and (C)
the
filing of final Transaction Documents (including signature pages thereto)
with
the Commission and Canadian Securities Commissions and (ii) to the extent
such
disclosure is required by law or Trading Market regulations, in which case
the
Company shall provide the Purchasers with prior notice of such disclosure
permitted under this clause (ii). By executing this Agreement, the Purchaser
acknowledges that, in connection with the transactions contemplated by this
Agreement, (A) the Company may deliver to the Ontario Securities Commission
and
other applicable securities regulatory authorities information respecting
the
Purchaser’s name, address and telephone number, the number and type of
Securities purchased, the total purchase price, the date of acquisition of
the
Securities by the Purchaser and the prospectus and registration exemptions
relied upon by the Company regarding the issuance of the Securities to the
Purchaser, (B) the information described in (A) is being collected indirectly
by
the Ontario Securities Commission and other applicable securities regulatory
authorities under the authority granted to it in securities legislation and
for
the purposes of the administration and enforcement of the securities legislation
of Ontario and other applicable jurisdictions, and (C) if the Purchaser has
questions or comments regarding the indirect collection of personal information
by the Ontario Securities Commission it should contact: Administrative Assistant
to the Director of Corporate Finance, Ontario Securities Commission, Suite
1903,
Box 0000 Xxxxx Xxxxxx Xxxx, Xxxxxxx, Xxxxxxx X0X 0X0, telephone: (000) 000-0000,
facsimile: (000) 000-0000.
4.5 Shareholder
Rights Plan. No claim will be made or enforced by the Company or, with the
consent of the Company, any other Person, that any Purchaser is an “Acquiring
Person” under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover
plan or arrangement in effect or hereafter adopted by the Company, or that
any
Purchaser could be deemed to trigger the provisions of any such plan or
arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the
Purchasers.
4.6 Non-Public
Information. Except with respect to the material terms and conditions of the
transactions contemplated by the Transaction Documents, the Company covenants
and agrees that neither it nor any other Person acting on its behalf will
provide any Purchaser or its agents or counsel with any information that the
Company believes constitutes material non-public information, unless prior
thereto such Purchaser shall have executed a written agreement regarding the
confidentiality and use of such information. The Company understands and
confirms that each Purchaser shall be relying on the foregoing covenant in
effecting transactions in securities of the Company.
25
4.7 Use
of Proceeds. The Company shall use the net proceeds from the sale of the
Securities hereunder for working capital purposes and shall not use such
proceeds for the satisfaction of any portion of the Company’s debt (other than
payment of trade payables in the ordinary course of the Company’s business and
prior practices), or to redeem any Common Stock or Common Stock Equivalents
or
to settle any outstanding litigation.
4.8 Indemnification
of Purchasers. Subject to the provisions of this Section 4.8, the Company
will indemnify and hold each Purchaser and its directors, officers,
shareholders, members, partners, employees and agents (and any other Persons
with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title), each Person who
controls such Purchaser (within the meaning of Section 15 of the Securities
Act
and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a
functionally equivalent role of a Person holding such titles notwithstanding
a
lack of such title or any other title) of such controlling persons (each, a
“Purchaser Party”) harmless from any and all losses, liabilities, obligations,
claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys’ fees and
costs of investigation that any such Purchaser Party may suffer or incur as
a
result of or relating to (a) any breach of any of the representations,
warranties, covenants or agreements made by the Company in this Agreement or
in
the other Transaction Documents or (b) any action instituted against a Purchaser
in any capacity, or any of them or their respective Affiliates, by any
stockholder of the Company who is not an Affiliate of such Purchaser, with
respect to any of the transactions contemplated by the Transaction Documents
(unless such action is based upon a breach of such Purchaser’s representations,
warranties or covenants under the Transaction Documents or any agreements or
understandings such Purchaser may have with any such stockholder or any
violations by the Purchaser of state or federal securities laws or any conduct
by such Purchaser which constitutes fraud, gross negligence, willful misconduct
or malfeasance). If any action shall be brought against any Purchaser Party
in
respect of which indemnity may be sought pursuant to this Agreement, such
Purchaser Party shall promptly notify the Company in writing, and the Company
shall have the right to assume the defense thereof with counsel of its own
choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party
shall
have the right to employ separate counsel in any such action and participate
in
the defense thereof, but the fees and expenses of such counsel shall be at
the
expense of such Purchaser Party except to the extent that (i) the employment
thereof has been specifically authorized by the Company in writing, (ii) the
Company has failed after a reasonable period of time to assume such defense
and
to employ counsel or (iii) in such action there is, in the reasonable opinion
of
such separate counsel, a material conflict on any material issue between the
position of the Company and the position of such Purchaser Party, in which
case
the Company shall be responsible for the reasonable fees and expenses of no
more
than one such separate counsel. The Company will not be liable to any Purchaser
Party under this Agreement (i) for any settlement by a Purchaser Party effected
without the Company’s prior written consent, which shall not be unreasonably
withheld or delayed; or (ii) to the extent, but only to the extent that a loss,
claim, damage or liability is attributable to any Purchaser Party’s breach of
any of the representations, warranties, covenants or agreements made by such
Purchaser Party in this Agreement or in the other Transaction
Documents.
26
4.9 Reservation
of Common Stock.
As of the date hereof, the Company has reserved and the Company shall continue
to reserve and keep available at all times, free of preemptive rights, a
sufficient number of shares of Common Stock for the purpose of enabling the
Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant
to any exercise of the Warrants. The Company is authorized to issue an unlimited
number of shares of Common Stock. If after the Closing Date, the Company amends
its articles or certificate of incorporation or similar charter document to
limit the number of shares of Common Stock that the Company is authorized to
issue, it shall maintain a reserve from its duly authorized shares of Common
Stock for issuance pursuant to the Transaction Documents in such amount as
may
be required to fulfill its obligations in full under the Transaction
Documents.
4.10 Listing
of Common Stock.(a)
The Company hereby agrees to use commercially reasonable best efforts to
maintain the listing of the Common Stock on a Trading Market, and as soon as
reasonably practicable following the Closing (but not later than the earlier
of
the Effective Date and the first anniversary of the Closing Date) to list all
of
the Shares and Warrant Shares on such Trading Market. The Company further
agrees, if the Company applies to have the Common Stock traded on any other
Trading Market, it will include in such application all of the Shares and
Warrant Shares, and will take such other action as is necessary to cause all
of
the Shares and Warrant Shares to be listed on such other Trading Market as
promptly as possible. The Company will take all action reasonably necessary
to
continue the listing and trading of its Common Stock on a Trading Market and
will comply in all respects with the Company’s reporting, filing and other
obligations under the bylaws or rules of the Trading Market.
4.11 Equal
Treatment of Purchasers. No consideration shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of
any
of the Transaction Documents unless the same consideration is also offered
to
all of the parties to the Transaction Documents. For clarification purposes,
this provision constitutes a separate right granted to each Purchaser by the
Company and negotiated separately by each Purchaser, and is intended for the
Company to treat the Purchasers as a class and shall not in any way be construed
as the Purchasers acting in concert or as a group with respect to the purchase,
disposition or voting of Securities or otherwise.
4.12 Participation
in Future Financing.
(a) From
the date hereof until the date that is the 24 month anniversary of the Closing
Date, upon any issuance by the Company or any of its Subsidiaries of Common
Stock or Common Stock Equivalents for cash consideration (a “Subsequent
Financing”),
each Purchaser shall have the right to participate in the Subsequent Financing
up to an amount equal to the lesser of (i) 100% of the Subsequent Financing
or
(ii) an amount equal to the aggregate Subscription Amount of all Purchasers
hereunder (the “Participation
Maximum”)
on the same terms, conditions and price provided for in the Subsequent
Financing.
(b) At
least 5 Trading Days prior to the closing of the Subsequent Financing, the
Company shall deliver to each Purchaser a written notice of its intention to
effect a Subsequent Financing (“Pre-Notice”),
which Pre-Notice shall ask such Purchaser if it wants to review the details
of
such financing (such additional notice, a “Subsequent
Financing Notice”).
Upon the request of a Purchaser, and only upon a request by such Purchaser,
for
a Subsequent Financing Notice, the Company shall promptly, but no later than
1
Trading Day after such request, deliver a Subsequent Financing Notice to such
Purchaser. The Subsequent Financing Notice shall describe in reasonable
detail the proposed terms of such Subsequent Financing, the amount of proceeds
intended to be raised thereunder and the Person or Persons through or with
whom
such Subsequent Financing is proposed to be effected and shall include a term
sheet or similar document relating thereto as an
attachment.
27
(c) Any
Purchaser desiring to participate in such Subsequent Financing must provide
written notice to the Company by not later than 5:30 p.m. (New York City time)
on the 5th
Trading Day after all of the Purchasers have received the Pre-Notice that the
Purchaser is willing to participate in the Subsequent Financing, the amount
of
the Purchaser’s participation, and that the Purchaser has such funds ready,
willing, and available for investment on the terms set forth in the Subsequent
Financing Notice. If the Company receives no notice from a Purchaser as of
such
5th
Trading Day, such Purchaser shall be deemed to have notified the Company that
it
does not elect to participate.
(d) If
by 5:30 p.m. (New York City time) on the 5th
Trading Day after all of the Purchasers have received the Pre-Notice,
notifications by the Purchasers of their willingness to participate in the
Subsequent Financing (or to cause their designees to participate) is, in the
aggregate, less than the total amount of the Subsequent Financing, then the
Company may effect the remaining portion of such Subsequent Financing on the
terms and with the Persons set forth in the Subsequent Financing Notice.
(e) If
by 5:30 p.m. (New York City time) on the 5th
Trading Day after all of the Purchasers have received the Pre-Notice, the
Company receives responses to a Subsequent Financing Notice from Purchasers
seeking to purchase more than the aggregate amount of the Participation Maximum,
each such Purchaser shall have the right to purchase its Pro Rata Portion (as
defined below) of the Participation Maximum. “Pro
Rata Portion”
means the ratio of (x) the Subscription Amount of Securities purchased on the
Closing Date by a Purchaser participating under this Section 4.12 and (y) the
sum of the aggregate Subscription Amounts of Securities purchased on the Closing
Date by all Purchasers participating under this Section 4.12.
(f) The
Company must provide the Purchasers with a second Subsequent Financing Notice,
and the Purchasers will again have the right of participation set forth above
in
this Section 4.12, if the Subsequent Financing subject to the initial Subsequent
Financing Notice is not consummated for any reason on the terms set forth in
such Subsequent Financing Notice within 60 Trading Days after the date of the
initial Subsequent Financing Notice.
(g) Notwithstanding
the foregoing, this Section 4.12 shall not apply in respect of (i)
an
Exempt Issuance
or (ii) an underwritten public offering of Common Stock.
28
4.13 Subsequent
Equity Sales.
(a) From
the date hereof until 90 days after the earlier of (i) the TSX Legend Removal
Date or (ii) the Effective Date, neither the Company nor any Subsidiary shall
issue shares of Common Stock or Common Stock Equivalents; provided,
however,
the 90 day period set forth in this Section 4.13 shall be extended for the
number of Trading Days during such period in which trading in the Common Stock
is suspended by any Trading Market.
(b) From
the date hereof until such time as no Purchaser holds any Warrants, the Company
shall be prohibited from effecting or entering into an agreement to effect any
Subsequent Financing involving a Variable Rate Transaction. “Variable
Rate Transaction”
means a transaction in which the Company issues or sells (i) any debt or equity
securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at
a
conversion, exercise or exchange rate or other price that is based upon and/or
varies with the trading prices of or quotations for the shares of Common Stock
at any time after the initial issuance of such debt or equity securities, or
(B)
with a conversion, exercise or exchange price that is subject to being reset
at
some future date after the initial issuance of such debt or equity security
or
upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock or
(ii) enters into any agreement, including, but not limited to, an equity line
of
credit, whereby the Company may sell securities at a future determined price.
Any Purchaser shall be entitled to obtain injunctive relief against the Company
to preclude any such issuance, which remedy shall be in addition to any right
to
collect damages.
(c) Notwithstanding
the foregoing, this Section 4.13 shall not apply in respect of an Exempt
Issuance, except that no Variable Rate Transaction shall be an Exempt
Issuance.
4.14 Short
Sales and Confidentiality After The Date Hereof. Each Purchaser severally
and not jointly with the other Purchasers, covenants that neither it nor any
Affiliate acting on its behalf or pursuant to any understanding with it will
execute any Short Sales during the period commencing at the Discussion Time
and
ending at the time that the transactions contemplated by this Agreement are
first publicly announced as described in Section 4.4.
Each
Purchaser, severally and not jointly with the other Purchasers, covenants that
until such time as the transactions contemplated by this Agreement are publicly
disclosed by the Company as described in Section 4.4, such Purchaser will
maintain the confidentiality of the existence and terms of this transaction
and
the information included in the Disclosure Schedules. Each Purchaser
understands and acknowledges, and agrees, severally and not jointly with any
other Purchaser, to act in a manner that will not violate the positions of
the
Commission as set forth in Item 65, Section A, of the Manual of Publicly
Available Telephone Interpretations, dated July 1997, compiled by the Office
of
Chief Counsel, Division of Corporation Finance. Notwithstanding
the foregoing, no Purchaser makes any representation, warranty or covenant
hereby that it will not engage in Short Sales in the securities of the Company
after the time that the transactions contemplated by this Agreement are first
publicly announced as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment
vehicle whereby separate portfolio managers manage separate portions of such
Purchaser’s assets and the portfolio managers have no direct knowledge of the
investment decisions made by the portfolio managers managing other portions
of
such Purchaser’s assets,
29
the
covenant set forth above shall only apply with respect to the portion of
assets
managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement.
4.15 Delivery
of Securities After Closing. The Company shall deliver, or cause to be
delivered, the respective Securities purchased by each Purchaser to such
Purchaser within 3 Trading Days of the Closing Date.
4.16 Form
D; Blue Sky and other filings. The Company agrees to timely file a Form D
with respect to the Securities as required under Regulation D and to provide
a
copy thereof, promptly upon request of any Purchaser. The Company shall take
such action as the Company shall reasonably determine is necessary in order
to
obtain an exemption for, or to qualify the Securities for, sale to the
Purchasers at the Closing under applicable securities or “Blue Sky” laws of the
states of the United States, and shall provide evidence of such actions promptly
upon request of any Purchaser. On or before the 10th
calendar day following the Closing Date, the Company shall file a Form 45-106F1,
as applicable, under Canadian Securities Laws.
4.17 Capital
Changes. Until the one year anniversary of the Effective Date, the Company
shall not undertake a reverse or forward stock split or reclassification of
the
Common Stock without the prior written consent of the Purchasers holding a
majority in interest of the Shares.
ARTICLE
V.
MISCELLANEOUS
5.1 Termination.
This Agreement may be terminated by any Purchaser, as to such Purchaser’s
obligations hereunder only and without any effect whatsoever on the obligations
between the Company and the other Purchasers, by written notice to the other
parties, if the Closing has not been consummated on or before March 30, 2007;
provided, however, that no such termination will affect the right of any party
to xxx for any breach by the other party (or parties).
5.2 Fees
and Expenses. At the Closing, the Company has agreed to reimburse Midsummer
Capital, LLC (“Midsummer”) the non-accountable sum of USD$20,000, for its legal
fees and expenses, none of which has been paid prior to the Closing. The Company
shall deliver, prior to the Closing, a completed and executed copy of the
Closing Statement, attached hereto as Annex A. Except as expressly set forth
in
the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and
all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company
shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied
in connection with the delivery of any Securities to the
Purchasers.
5.3 Entire
Agreement. The Transaction Documents, together with the exhibits and
schedules thereto, contain the entire understanding of the parties with respect
to the subject matter hereof and supersede all prior agreements and
understandings, oral or written, with respect to such matters, which the parties
acknowledge have been merged into such documents, exhibits and
schedules.
30
5.4 Notices.
Any and all notices or other communications or deliveries required or permitted
to be provided hereunder shall be in writing and shall be deemed given and
effective on the earliest of (a) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number set forth
on
the signature pages attached hereto prior to 5:30 p.m. (New York City time)
on a
Trading Day, (b) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile at the facsimile number
set
forth on the signature pages attached hereto on a day that is not a Trading
Day
or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the
2nd
Trading Day following the date of mailing, if sent by a U.S. or Canadian
nationally recognized overnight courier service, or (d) upon actual receipt
by
the party to whom such notice is required to be given. The address for such
notices and communications shall be as set forth on the signature pages attached
hereto.
5.5 Amendments;
Waivers. No provision of this Agreement may be waived or amended except in a
written instrument signed, in the case of an amendment, by the Company and
the
Purchasers of at least 85% of the Shares still held by the Purchasers or, in
the
case of a waiver, by the party against whom enforcement of any such waived
provision is sought. No waiver of any default with respect to any provision,
condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any
other provision, condition or requirement hereof, nor shall any delay or
omission of any party to exercise any right hereunder in any manner impair
the
exercise of any such right.
5.6 Headings.
The headings herein are for convenience only, do not constitute a part of this
Agreement and shall not be deemed to limit or affect any of the provisions
hereof.
5.7 Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit
of the parties and their successors and permitted assigns. The Company may
not
assign this Agreement or any rights or obligations hereunder without the prior
written consent of each Purchaser (other than by merger). Any Purchaser may
assign any or all of its rights under this Agreement to any Person to whom
such
Purchaser assigns or transfers any Securities, provided such transferee agrees
in writing to be bound, with respect to the transferred Securities, by the
provisions of the Transaction Documents that apply to the
“Purchasers.”
5.8 No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is
not
for the benefit of, nor may any provision hereof be enforced by, any other
Person, except as otherwise set forth in Section 4.8.
5.9 Governing
Law. All questions concerning the construction, validity, enforcement and
interpretation of the Transaction Documents shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York,
without regard to the principles of conflicts of law thereof. Each party agrees
that all legal proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other
Transaction Documents (whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of
New
York. Each party hereby irrevocably submits to the exclusive jurisdiction of
the
state and federal courts sitting in the City of New York, borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or
with
any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that
such suit, action or proceeding is improper or is an inconvenient venue for
such
proceeding. Each party hereby irrevocably waives personal service of process
and
consents to process being served in any such suit, action or proceeding by
mailing a copy thereof via registered or certified mail or overnight delivery
(with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good
and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other
manner permitted by law. If either party shall commence an action or proceeding
to enforce any provisions of the Transaction Documents, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for
its reasonable attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or
proceeding.
31
5.10 Survival.
The representations and warranties contained herein shall survive the Closing
and the delivery of the Shares and Warrant Shares.
5.11 Execution.
This Agreement may be executed in two or more counterparts, all of which when
taken together shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to
the
other party, it being understood that both parties need not sign the same
counterpart. In the event that any signature is delivered by facsimile
transmission or by e-mail delivery of a “.pdf” format data file, such signature
shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such
facsimile or “.pdf” signature page were an original thereof.
5.12 Severability.
If any term, provision, covenant or restriction of this Agreement is held by
a
court of competent jurisdiction to be invalid, illegal, void or unenforceable,
the remainder of the terms, provisions, covenants and restrictions set forth
herein shall remain in full force and effect and shall in no way be affected,
impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same
or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the
intention of the parties that they would have executed the remaining terms,
provisions, covenants and restrictions without including any of such that may
be
hereafter declared invalid, illegal, void or unenforceable.
5.13 Rescission
and Withdrawal Right. Notwithstanding anything to the contrary contained in
(and without limiting any similar provisions of) any of the other Transaction
Documents, whenever any Purchaser exercises a right, election, demand or option
under a Transaction Document and the Company does not timely perform its related
obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to
the
Company, any relevant notice, demand or election in whole or in part without
prejudice to its future actions and rights; provided, however, in the case
of a
rescission of an exercise of a Warrant, the Purchaser shall be required to
return any shares of Common Stock delivered in connection with any such
rescinded exercise notice.
32
5.14 Replacement
of Securities. If any certificate or instrument evidencing any Securities is
mutilated, lost, stolen or destroyed, the Company shall issue or cause to be
issued in exchange and substitution for and upon cancellation thereof (in the
case of mutilation), or in lieu of and substitution therefor, a new certificate
or instrument, but only upon receipt of evidence reasonably satisfactory to
the
Company of such loss, theft or destruction. The applicant for a new certificate
or instrument under such circumstances shall also pay any reasonable third-party
costs (including customary indemnity) associated with the issuance of such
replacement Securities.
5.15 Remedies.
In addition to being entitled to exercise all rights provided herein or granted
by law, including recovery of damages, each of the Purchasers and the Company
will be entitled to specific performance under the Transaction Documents. The
parties agree that monetary damages may not be adequate compensation for any
loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agrees to waive and not to assert in any action
for specific performance of any such obligation the defense that a remedy at
law
would be adequate.
5.16 Payment
Set Aside. To the extent that the Company makes a payment or payments to any
Purchaser pursuant to any Transaction Document or a Purchaser enforces or
exercises its rights thereunder, and such payment or payments or the proceeds
of
such enforcement or exercise or any part thereof are subsequently invalidated,
declared to be fraudulent or preferential, set aside, recovered from, disgorged
by or are required to be refunded, repaid or otherwise restored to the Company,
a trustee, receiver or any other person under any law (including, without
limitation, any bankruptcy law, state or federal law, common law or equitable
cause of action), then to the extent of any such restoration the obligation
or
part thereof originally intended to be satisfied shall be revived and continued
in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred.
5.17 Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each
Purchaser under any Transaction Document are several and not joint with the
obligations of any other Purchaser, and no Purchaser shall be responsible in
any
way for the performance or non-performance of the obligations of any other
Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant
thereto, shall be deemed to constitute the Purchasers as a partnership, an
association, a joint venture or any other kind of entity, or create a
presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the
Transaction Documents. Each Purchaser shall be entitled to independently protect
and enforce its rights, including without limitation, the rights arising out
of
this Agreement or out of the other Transaction Documents, and it shall not
be
necessary for any other Purchaser to be joined as an additional party in any
proceeding for such purpose. Each Purchaser has been represented by its own
separate legal counsel in their review and negotiation of the Transaction
Documents. For reasons of administrative convenience only, Purchasers and their
respective counsel have chosen to communicate with the Company through FWS.
FWS
does not represent all of the Purchasers but only Midsummer. The Company has
elected to provide all Purchasers with the same terms and Transaction Documents
for the convenience of the Company and not because it was required or requested
to do so by the Purchasers.
33
5.18 Liquidated
Damages. The Company’s obligations to pay any partial liquidated damages or
other amounts owing under the Transaction Documents is a continuing obligation
of the Company and shall not terminate until all unpaid partial liquidated
damages and other amounts have been paid notwithstanding the fact that the
instrument or security pursuant to which such partial liquidated damages or
other amounts are due and payable shall have been canceled.
5.19 Construction.
The parties agree that each of them and/or their respective counsel has reviewed
and had an opportunity to revise the Transaction Documents and, therefore,
the
normal rule of construction to the effect that any ambiguities are to be
resolved against the drafting party shall not be employed in the interpretation
of the Transaction Documents or any amendments hereto.
5.20 Waiver
of Jury Trial. In any action, suit or proceeding in any jurisdiction brought
by any party against any other party, the parties each knowingly and
intentionally, to the greatest extent permitted by applicable law, hereby
absolutely, unconditionally, irrevocably and expressly waives forever trial
by
jury.
(Signature
Pages Follow)
34
IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase
Agreement to be duly executed by their respective authorized signatories as
of
the date first indicated above.
|
Address
for Notice:
|
By:__________________________________________
Name:
Title:
|
Fax:
|
With
a copy to (which shall not constitute notice):
|
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK
SIGNATURE
PAGE FOR PURCHASER FOLLOWS]
35
[PURCHASER
SIGNATURE PAGES TO XXX.XX SECURITIES PURCHASE AGREEMENT]
IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement
to be duly executed by their respective authorized signatories as of the date
first indicated above.
Name
of Purchaser:
_______________________________________________________________________________________________________________
Signature
of Authorized Signatory of Purchaser:
________________________________________________________________________________________
Name
of Authorized Signatory:
______________________________________________________________________________________________________
Title
of Authorized Signatory:
_______________________________________________________________________________________________________
Email
Address of
Purchaser:_________________________________________________________________________________________________________
Fax
Number of Purchaser:
___________________________________________________________________________________________________________
Address
for Notice of Purchaser:
Address
for Delivery of Securities for Purchaser (if not same as above):
Subscription
Amount:
Warrant
Shares:
EIN
Number: [PROVIDE
THIS UNDER SEPARATE COVER]
Telephone
Number of Purchaser: [PROVIDE
THIS UNDER SEPARATE COVER]
[SIGNATURE
PAGES CONTINUE]
36
Annex
A
CLOSING
STATEMENT
Pursuant
to the attached Securities Purchase Agreement, dated as of the date hereto,
the
purchasers shall purchase up to Cdn.$3,889,878 of Shares and Warrants from
PreMD
Inc. (the “Company”).
All funds will be wired into an account maintained by the Company. All funds
will be disbursed in accordance with this Closing Statement.
Disbursement
Date: March
___, 2007
I.
PURCHASE
PRICE
|
|
Gross
Proceeds to be Received
|
$
|
II. DISBURSEMENTS
|
|
|
$
|
Midsummer
Capital
|
USD$20,000
|
$
|
|
$
|
|
$
|
|
Total
Amount Disbursed:
|
$
|
WIRE
INSTRUCTIONS:
|
|
To:
_____________________________________
|
|
To:
_____________________________________
|
37
Annex
B
XXXX
& BERLIS WIRE INSTRUCTIONS
The
Toronto Dominion Bank
King
& Bay Branch, TD Centre
00
Xxxx Xxxxxx Xxxx
Xxxxxxx,
Xxxxxxx
X0X
0X0
Xxxx
& Berlis LLP Trust Account
Transit
No: 10202
Swift
Code: XXXXXXXXXXX
ABA
No: 000000000
Canadian
Dollar Trust Account No: 0000000
Correspondent
Bank - Bank of America, New York
38
Annex
C
CERTIFICATE
OF ACCREDITED INVESTOR
PLEASE
XXXX YOUR INITIALS BESIDE THE CATEGORY TO WHICH YOU
BELONG
In
connection with the purchase by the undersigned purchaser (the “Purchaser”)
of units (the “Units”)
of PreMD Inc. (the “Corporation”),
the Purchaser or the undersigned on behalf of the Purchaser, as the case may
be,
certifies for the benefit of the Corporation that the Purchaser, or the
beneficial purchaser(s) for whom the Purchaser is acting (if applicable), is
a
resident of, or the purchase and sale of securities to the Purchaser is
otherwise subject to the securities legislation of, a Province or Territory
of
Canada, and the Purchaser is (and will at the time of acceptance of the
Subscription be) an accredited investor within the meaning of National
Instrument 45-106 - Prospectus
and Registration Exemptions
(“NI
45-106”)
because the Purchaser, or beneficial purchaser(s) is/are:
_____ |
(a)
|
a
Canadian financial institution, or a bank listed in Schedule
III of the
Bank
Act
(Canada);
|
_____ |
(b)
|
the
Business Development Bank of Canada incorporated under the Business
Development Bank Act
(Canada);
|
_____ |
(c)
|
a
subsidiary of any person referred to in paragraphs (a) or (b), if
the
person owns all of the voting securities of the subsidiary, except
the
voting securities required by law to be owned by directors of that
subsidiary;
|
_____ |
(d)
|
a
person registered under the securities legislation of a jurisdiction
of
Canada as an adviser or dealer, other than a person registered solely
as a
limited market dealer under one or both of the Securities
Act
(Ontario) or the Securities
Act
(Newfoundland and Labrador);
|
______
|
(e)
|
an
individual registered or formerly registered under the securities
legislation of a jurisdiction of Canada as a representative of a
person
referred to in paragraph (d);
|
_____ |
(f)
|
the
Government of Canada or a jurisdiction of Canada, or any crown
corporation, agency or wholly owned entity of the Government of Canada
or
a jurisdiction of Canada;
|
_____ |
(g)
|
a
municipality, public board or commission in Canada and a metropolitan
community, school board, the Comité de gestion de la taxe scolaire de
l’ le de Montréal or an intermunicipal management board in
Québec;
|
_____ |
(h)
|
any
national, federal, state, provincial, territorial or municipal government
of or in any foreign jurisdiction, or any agency of that
government;
|
_____ |
(i)
|
a
pension fund that is regulated by either the Office of the Superintendent
of Financial Institutions (Canada) or a pension commission or similar
regulatory authority of a jurisdiction of
Canada;
|
_____ |
(j)
|
an
individual who, either alone or with a spouse, beneficially owns,
directly
or indirectly, financial assets having an aggregate realizable value
that
before taxes, but net of any related liabilities, exceeds
$1,000,000;
|
_____ |
(k)
|
an
individual whose net income before taxes exceeded $200,000 in each
of the
two most recent calendar years or whose net income before taxes combined
with that of a spouse exceeded $300,000 in each of the two most recent
calendar years and who, in either case, reasonably expects to exceed
that
net income level in the current calendar
year;
|
_____ |
(l)
|
an
individual who, either alone or with a spouse, has net assets of
at least
$5,000,000;
|
39
_____ |
(m)
|
a
person, other than an individual or an investment fund, that has
net
assets of at least $5,000,000, as shown on its most recently prepared
financial statements;
|
_____ |
(n)
|
an
investment fund that distributes or has distributed its securities
only
to:
|
(i)
|
a person that is or was an accredited investor at the time of the distribution, |
(ii)
|
a
person that acquires or acquired securities in the circumstances
referred
to in sections 2.10 of NI 45-106 (where the person subscribes for a
minimum amount investment) and 2.19 of NI 45-106 (where the person
makes
an additional investment in investment funds),
or
|
(iii)
|
a
person described in paragraph (i) or (ii) that acquires or acquired
securities under section 2.18 of NI 45-106 (investment fund
reinvestment);
|
_____ |
(o)
|
an
investment fund that distributes or has distributed securities under
a
prospectus in a jurisdiction of Canada for which the regulator or,
in
Québec, the securities regulatory authority, has issued a
receipt;
|
_____ |
(p)
|
a
trust company or trust corporation registered or authorized to carry
on
business under the Trust
and Loan Companies Act (Canada)
or under comparable legislation in a jurisdiction of Canada or a
foreign
jurisdiction acting on behalf of a fully managed account managed
by the
trust company or trust corporation, as the case may
be;
|
_____ |
(q)
|
a
person acting on behalf of a fully managed account managed by that
person,
if that person
|
(i)
|
is
registered or authorized to carry on business as an adviser or the
equivalent under the securities legislation of a jurisdiction of
Canada or
a foreign jurisdiction, and
|
(ii)
|
in
Ontario, is purchasing a security that is not a security of an investment
fund;
|
_____ |
(r)
|
a
registered charity under the Income
Tax Act (Canada)
that, in regard to the trade, has obtained advice from an eligibility
adviser or an adviser registered under the securities legislation
of the
jurisdictions of the registered charity to give advice on the securities
being traded;
|
_____ |
(s)
|
an
entity organized in a foreign jurisdiction that is analogous to any
of the
entities referred to in paragraphs (a) to (d) or paragraph (i) in
form and
function;
|
_____ |
(t)
|
a
person in respect of which all of the owners of interests, direct,
indirect or beneficial, except the voting securities required by
law to be
owned by directors, are persons that are accredited
investors;
|
_____ |
(u)
|
an
investment fund that is advised by a person registered as an adviser
or a
person that is exempt from registration as an adviser;
or
|
_____ |
(v)
|
a
person that is recognized or designated by the securities regulatory
authority or, except in Ontario and Québec, the regulator
as
|
(i) an
accredited investor, or
(ii)
|
an
exempt purchaser in Alberta or British Columbia after NI 45-106 comes
into
force.
|
40
Date: | |||
Print
name of Purchaser
|
|||
Signature
|
|||
Name
(please print)
|
|||
Title
|
|||
AND,
|
|||
if
this certificate is being executed on behalf of the Purchaser by
a trustee
or agent, fill in below:
|
|||
Print
name of trustee or agent
as
trustee or agent of the Purchaser
|
|||
|
|||
Signature
|
|||
Name
(please print)
|
|||
Title
|
41
Interpretative
Aids
The
following definitions relate to certain of the categories of NI 45-106 -
Accredited Investor set forth above:
(a)
|
“bank”
means a bank named in Schedule I or II of the Bank
Act
(Canada);
|
(b) | “Canadian financial institution” means |
(i) |
an association governed by the
Cooperative
Credit Associations Act (Canada)
or a central cooperative credit society for which an order has been
made
under section 473(1) of that Act,
or
|
(ii)
|
a
bank, loan corporation, trust company, trust corporation, insurance
company, treasury branch, credit union, caisse populaire, financial
services cooperative, or league that, in each case, is authorized
by an
enactment of Canada or a jurisdiction of Canada to carry on business
in
Canada or a jurisdiction of Canada;
|
(c)
|
“control
person” has the same meaning as in securities legislation except in
Manitoba, Newfoundland and Labrador, Northwest Territories, Nova
Scotia,
Nunavut, Ontario, Xxxxxx Xxxxxx Island and Québec where control person
means any person that holds or is one of a combination of persons
that
holds
|
(i) | a sufficient number of any of the securities of an issuer so as to affect materially the control of the issuer, or |
(ii)
|
more
than 20% of the outstanding voting securities of an issuer except
where
there is evidence showing that the holding of those securities does
not
affect materially the control of the
issuer;
|
(d) “director”
means:
(i)a
member of the board of directors of a company or an individual who performs
similar functions for a company, and
(ii)
|
with
respect to a person that is not a company, an individual who performs
functions similar to those of a director of a
company;
|
(e) “eligibility
adviser” means
(i)
|
a
person that is registered as an investment dealer or in an equivalent
category of registration under the securities legislation of the
jurisdiction of a purchaser and authorized to give advice with respect
to
the type of security being distributed,
and
|
(ii)
|
in
Saskatchewan and Manitoba, also means a lawyer who is a practicing
member
in good standing with a law society of a jurisdiction of Canada or
a
public accountant who is a member in good standing of an institute
or
association of chartered accountants, certified general accountants
or
certified management accountants in a jurisdiction of Canada provided
that
the lawyer or public accountant must
not
|
42
(A)
|
have
a professional, business or personal relationship with the issuer,
or any
of its directors, executive officer, founders, or control persons,
and
|
(B)
|
have
acted for or been retained personally or otherwise as an employee,
executive officer, director, associate or partner of a person that
has
acted for or been retained by the issuer or any of its directors,
executive officers, founders or control persons within the previous
12
months;
|
(f)
|
“executive
officer” means, for an issuer, an individual who
is
|
(i)
|
a
chair, vice-chair or president,
|
(ii)
|
a
vice-president in charge of a principal business unit, division or
function including sales, finance or
production,
|
(iii)
|
an
officer of the issuer or any of its subsidiaries and who performs
a
policy-making function in respect of the issuer,
or
|
(iv)
|
performing
a policy-making function in respect of the
issuer;
|
(g)
|
“financial
assets” means
|
(i)
|
cash,
|
(ii)
|
securities,
or
|
(iii)
|
a
contract of insurance, a deposit or an evidence of a deposit that
is not a
security for the purposes of securities
legislation;
|
(h)
|
“founder”
means, in respect of an issuer, a person
who,
|
(i)
|
acting
alone, in conjunction, or in concert with one or more persons, directly
or
indirectly, takes the initiative in founding, organizing or substantially
reorganizing the business of the issuer,
and
|
(ii)
|
at
the time of the trade is actively involved in the business of the
issuer;
|
(i)
|
“foreign
jurisdiction” means a country other than Canada or a political subdivision
of a country other than Canada;
|
(j)
|
“fully
managed account” means an account of a client for which a person makes the
investment decisions if that person has full discretion to trade
in
securities for the account without requiring the client's express
consent
to a transaction;
|
(k)
|
“investment
fund” has the same meaning as in National Instrument 81-106 - Investment
Fund Continuous Disclosure;
|
(l)
|
“jurisdiction”
means a province or territory of Canada except when used in the term
foreign jurisdiction;
|
43
(m)
|
“non-redeemable
investment fund” means an issuer,
|
(i)
|
where
contributions of securityholders are pooled for
investment,
|
(ii)
|
where
securityholders do not have day-to-day control over the management
and
investment decisions of the issuer, whether or not they have the
right to
be consulted or to give directions,
and
|
(iii)
|
whose
securities do not entitle the securityholder to receive on demand,
or
within a specified period after demand, an amount computed by reference
to
the value of a proportionate interest in the whole or in part of
the net
assets of the issuer;
|
(n)
|
“person”
includes
|
(i)
|
an
individual,
|
(ii)
|
a
corporation,
|
(iii)
|
a
partnership, trust, fund and an association, syndicate, organization
or
other organized group of persons, whether incorporated or not,
and
|
(iv)
|
an
individual or other person in that person's capacity as a trustee,
executor, administrator or personal or other legal
representative;
|
(o)
|
“regulator”
means, for the local jurisdiction, the Executive Director as defined
under
securities legislation of the local
jurisdiction;
|
(p)
|
“related
liabilities” means
|
(i)
|
liabilities
incurred or assumed for the purpose of financing the acquisition
or
ownership of financial assets, or
|
(ii)
|
liabilities
that are secured by financial
assets;
|
(q)
|
“Schedule
III bank” means an authorized foreign bank named in Schedule III of the
Bank
Act
(Canada);
|
(r)
|
“spouse”
means, an individual who,
|
(i)
|
is
married to another individual and is not living separate and apart
within
the meaning of the Divorce
Act
(Canada), from the other
individual,
|
(ii)
|
is
living with another individual in a marriage-like relationship, including
a marriage-like relationship between individuals of the same gender,
or
|
(iii)
|
in
Alberta, is an individual referred to in paragraph (i) or (ii) above,
or
is an adult interdependent partner within the meaning of the Adult
Interdependent Relationships Act (Alberta);
|
(s)
|
“subsidiary”
means an issuer that is controlled directly or indirectly by another
issuer and includes a subsidiary of that
subsidiary;
|
44
(t)
|
An
issuer is an affiliate of another issuer
if:
|
(i)
|
one
of them is the subsidiary of the other,
or
|
(ii)
|
each
of them is controlled by the same person,
and
|
(u)
|
A
person (first person) is considered to control another person (second
person) if:
|
(i)
|
the
first person, directly or indirectly, beneficially owns or exercises
control or direction over securities of the second person carrying
votes
which, if exercised, would entitle the first person to elect a majority
of
the directors of the second person, unless that first person holds
the
voting securities only to secure an
obligation,
|
(ii)
|
the
second person is a partnership, other than a limited partnership,
and the
first person holds more than 50% of the interest of the partnership,
or
|
(iii)
|
the
second person is a limited partnership and the general partner of
the
limited partnership is the first
person.
|
All
monetary references are in Canadian dollars.
45